TABLE 1.
Patient Characteristics
| Patients With CD (n = 1368) | Patients With UC (n = 1030) | |
|---|---|---|
| Current age, mean (SD), y | 42.4 (14.2) | 44.2 (14.1) |
| Age at diagnosis, mean (SD), y | 32.4 (14.3) | 36.8 (14.2) |
| Female, % | 60 | 55 |
| IBD severity | ||
| Moderate/severe, %* | 93 | 78 |
| Ever required hospitalization, % | 71 | 47 |
| Treatment, % current/% ever | ||
| Corticosteroid | 27/76 | 29/74 |
| 5-ASA | 24/57 | 45/68 |
| Immunomodulator | 26/52 | 19/37 |
| TNF inhibitor | 32/52 | 22/34 |
| Nonpharmacologic treatment | 16/28 | 16/24 |
| Anti-integrin | 9/15 | 7/11 |
| Anti-interleukin-12/23 | 9/14 | 2/4 |
| JAK inhibitor | 2/5 | 4/5 |
| Other | 3/7 | 2/5 |
| Comorbid conditions, % | ||
| Anxiety | 33 | 31 |
| Depression | 31 | 25 |
| Upper gastrointestinal problems | 17 | 10 |
| Rheumatoid arthritis | 9 | 7 |
| Celiac disease | 6 | 4 |
| Type 1 diabetes | 6 | 4 |
*Patient-reported. For inclusion, the proportion of patients with mild disease was capped at 20%.
JAK indicates Janus kinase.